MedPath

Evaluation of inflammatory substances in the blood of patients with recurrent glioblastoma in treatment with inhalation of perillyl alcohol associated with reduced carbohydrate diet and supplementation with omega 3

Not Applicable
Conditions
Glioblastoma
C04.557.465.625.600.380.080.335
Registration Number
RBR-3byz2c
Lead Sponsor
Hospital Universitário Antônio Pedro
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot yet recruiting
Sex
Not specified
Target Recruitment
Not specified
Inclusion Criteria

Adults with glioblastoma; submitted to surgical procedure with the partial withdrawal of the tumor; who presented recurrences and are under chemotherapeutic treatment.

Exclusion Criteria

Participants who initiate immunotherapeutic treatment; or develop autoimmune; hepatic or renal disease; or discontinue the ketogenic diet; perillyl alcohol inhalation or supplement will be excluded.

Study & Design

Study Type
Intervention
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Survival free of progression of participants, monitored by magnetic resonance imaging after 1 year of study.
Secondary Outcome Measures
NameTimeMethod
The combined treatment is expected to stabilize tumor growth, which will be checked at baseline and after 2 months of study.
© Copyright 2025. All Rights Reserved by MedPath